FDA May Disclose Clinical Investigator Financial Data In Product Approvals
This article was originally published in The Pink Sheet Daily
Executive Summary
Final guidance on drug sponsors’ responsibilities for financial disclosures related to clinical investigators who participate revises definitions of due diligence and covered clinical studies from the draft published in 2011, but retains FDA’s statement that it may include such disclosures in the documents released upon product approval for marketing.